{
    "nctId": "NCT05749016",
    "briefTitle": "Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer",
    "officialTitle": "Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Locally Advanced HER2-Positive Breast Cancer: a Prospective, Single-arm, Multi-center Phase II Study",
    "overallStatus": "RECRUITING",
    "conditions": "Locally Advanced Breast Cancer, Chemotherapy Effect",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "pathologic complete response (pCR) rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age of minimum of 18 years to a maximum of 70 years; males or females\n* diagnosed as invasive breast carcinoma by preoperative needle core biopsy; patients with clinical stage of T1c to T4, N0-3, and M0, as defined by the American Joint Committee on Cancer AJCC Staging Manual, 8th Edition staging criteria\n* HER2-positive: an immunohistochemistry (IHC) score of 3+ or IHC 2+ and in situ hybridization ISH+/fluorescence in situ hybridization FISH+.\n* Left ventricular ejection fraction (LVEF) \u226550%\uff1b\n* Eastern Cooperative Oncology Group (ECOG) performance score was 0/1\uff1b\n* In the absence of blood transfusion or pharmacological treatment (granulocyte colony-stimulating factor/erythropoietin (EPO)/interleukin-11, etc.) within 14 days prior to the first treatment, and organ function must meet the following requirements: absolute neutrophil count (ANC) \u2265 1.5\u00d7109/L; platelets (PLT) \u2265 100\u00d7109/L; hemoglobin (Hb) \u2265 90g/L. Blood biochemistry: total bilirubin (TBIL) \u22641.5\u00d7ULN; ALT and AST \u22641.5\u00d7ULN; BUN and Cr \u22641.5\u00d7ULN; creatinine clearance \u226550mL/min (Cockcroft-Gault formula); total bilirubin (TBIL) \u22641.5\u00d7ULN; ALT and AST \u22641.5\u00d7ULN; BUN and Cr \u22641.5\u00d7ULN; creatinine clearance \u226550mL/min (Cockcroft-Gault formula);\n* Volunteered to participate in this study and signed informed consent.\n\nExclusion Criteria:\n\n* had a previous history of invasive breast cancer;\n* Bilateral breast cancer, inflammatory breast cancer (eg, erythema and/or skin involvement, and/or pathological findings of neoplastic cells in dermal lymphatic vessels);\n* Previous excisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes;\n* Previous systemic therapy for breast cancer\uff1b\n* History of previous life-threatening hypersensitivity reactions, or known hypersensitivity to any component of the study drug\uff1b\n* Participated in clinical trials of other drugs or medical devices within 4 weeks before the first medication, and received treatment with experimental drugs or devices\uff1b\n* Patients who have undergone major surgery within 28 days before the first dose, or plan to have major surgery during the study period\uff1b\n* Other malignancies within the past 5 years (except cervical cancer in situ, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ)\uff1b\n* Active hepatitis, active tuberculosis or other serious infectious diseases, etc., including but not limited to: active hepatitis C virus (HCV) infection (except for HCV antibody positive but RNA negative), or active hepatitis B virus (HBV) infection (hepatitis B Surface antigen positive and HBV-DNA copy number \\>2000 IU/mL) or bacteremia, severe infectious pneumonia and other serious infections requiring systemic treatment\n* History of immunodeficiency or other autoimmune diseases, including but not limited to human immunodeficiency virus (HIV) infection (HIV antibody positive), systemic lupus erythematosus, rheumatoid arthritis, or history of organ transplantation\uff1b\n* Those with the following history of cardiovascular and cerebrovascular diseases, including: (1) unstable angina; (2) arrhythmia requiring drug treatment or clinically significant; (3) myocardial infarction within 6 months; (4) cardiac arrhythmia Failure, second-degree and above atrioventricular block; (5) cerebral infarction (except lacunar infarction), cerebral hemorrhage and other diseases within 6 months\uff1b\n* Patients with poorly controlled hypertension (systolic blood pressure \\>160 mmHg and/or diastolic blood pressure \\>100 mmHg under regular drug control), or a history of hypertensive crisis or hypertensive encephalopathy\uff1b\n* Pregnant and breastfeeding female patients; women of childbearing age who have a positive pregnancy test during the screening period; patients who are unwilling to take effective contraceptive measures during the entire test period and within 6 months after the end of the medication\uff1b\n* Other conditions that the investigator considers inappropriate to participate in this trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}